- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Silas Inman | Authors
Articles
Phase 3 Study Explores Pamrevlumab for Unresectable LAPC
February 17, 2021
The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.
Gottlieb Addresses Coronavirus at Miami Breast Cancer Conference
March 09, 2020
Scott Gottlieb, MD, spoke about the spread of the novel coronavirus (COVID-19) during the keynote address at the 37th Annual Miami Breast Cancer Conference®.
CC-93269 Demonstrates Promising Dose-Dependent Efficacy in Heavily Pretreated Myeloma
December 07, 2019
CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.
Axi-Cel Improves OS in Patients with Refractory B-Cell Lymphoma
December 07, 2019
The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.